Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sonoma Pharmaceuticals, Inc. - Common Stock (NQ: SNOA )

2.730 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sonoma Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices
Via ACCESSWIRE
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States
Via ACCESSWIRE
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results
Via ACCESSWIRE
Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2025 Financial Results
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2023 Financial Results
Via ACCESSWIRE
Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada
Via ACCESSWIRE
Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences
Via ACCESSWIRE
Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
Via ACCESSWIRE
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution
Via ACCESSWIRE
Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line
Via ACCESSWIRE
Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock
Via ACCESSWIRE
Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-Diff
Via ACCESSWIRE
Sonoma Pharmaceuticals Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United States
Via ACCESSWIRE
Sonoma Pharmaceuticals Celebrates 20 Years of Selling Wound Care Products in Europe and Announces New Distributor in Ukraine
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results
Via ACCESSWIRE
Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores
Via ACCESSWIRE
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
Via ACCESSWIRE
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
Via ACCESSWIRE
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
Via ACCESSWIRE
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use
Via ACCESSWIRE
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
Via ACCESSWIRE
Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall Conference
Via ACCESSWIRE
Sonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common Stock
Via ACCESSWIRE
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
Via ACCESSWIRE
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial Results
Via ACCESSWIRE
Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory Board
Via ACCESSWIRE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.